Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1963 1
1964 2
1965 2
1967 3
1968 4
1969 1
1970 1
1971 1
1972 2
1973 5
1974 1
1975 2
1976 2
1977 3
1978 4
1979 17
1980 16
1981 18
1982 18
1983 21
1984 17
1985 13
1986 23
1987 25
1988 36
1989 25
1990 30
1991 30
1992 25
1993 38
1994 30
1995 26
1996 38
1997 39
1998 47
1999 37
2000 31
2001 36
2002 37
2003 43
2004 52
2005 56
2006 54
2007 55
2008 38
2009 56
2010 42
2011 48
2012 60
2013 56
2014 57
2015 61
2016 82
2017 70
2018 66
2019 78
2020 105
2021 52
Text availability
Article attribute
Article type
Publication date

Search Results

1,716 results
Results by year
Filters applied: . Clear all
Page 1
The liver-brain-gut neural arc maintains the Treg cell niche in the gut.
Teratani T, Mikami Y, Nakamoto N, Suzuki T, Harada Y, Okabayashi K, Hagihara Y, Taniki N, Kohno K, Shibata S, Miyamoto K, Ishigame H, Chu PS, Sujino T, Suda W, Hattori M, Matsui M, Okada T, Okano H, Inoue M, Yada T, Kitagawa Y, Yoshimura A, Tanida M, Tsuda M, Iwasaki Y, Kanai T. Teratani T, et al. Among authors: tsuda m. Nature. 2020 Sep;585(7826):591-596. doi: 10.1038/s41586-020-2425-3. Epub 2020 Jun 11. Nature. 2020. PMID: 32526765
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Kang YK, et al. Among authors: tsuda m. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. Lancet. 2017. PMID: 28993052 Clinical Trial.
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Boku N, et al. Among authors: tsuda m. Ann Oncol. 2019 Feb 1;30(2):250-258. doi: 10.1093/annonc/mdy540. Ann Oncol. 2019. PMID: 30566590 Free PMC article. Clinical Trial.
Microglia in the spinal cord and neuropathic pain.
Tsuda M. Tsuda M. J Diabetes Investig. 2016 Jan;7(1):17-26. doi: 10.1111/jdi.12379. Epub 2015 Jun 23. J Diabetes Investig. 2016. PMID: 26813032 Free PMC article. Review.
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N. Chen LT, et al. Among authors: tsuda m. Gastric Cancer. 2020 May;23(3):510-519. doi: 10.1007/s10120-019-01034-7. Epub 2019 Dec 20. Gastric Cancer. 2020. PMID: 31863227 Free PMC article. Clinical Trial.
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Yamada Y, et al. Among authors: tsuda m. Ann Oncol. 2015 Jan;26(1):141-148. doi: 10.1093/annonc/mdu472. Epub 2014 Oct 14. Ann Oncol. 2015. PMID: 25316259 Free article. Clinical Trial.
1,716 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page